The Essential Molecular Foundation
Targeted Genomic Profiling — 118 Actionable Genes
To fight cancer effectively, you need a highly accurate map of its vulnerabilities. Signature Baseline is our targeted, high-precision liquid biopsy. By extracting circulating tumour DNA (ctDNA) from a simple blood draw, this panel detects critical somatic variants across 118 highly actionable genes with exceptional sensitivity and specificity.
Designed for strategic precision, Signature Baseline analyzes the key oncogenes highlighted by global guidelines (NCCN, ASCO, ESMO, and FDA). It is engineered for patients who need affordable access to vital tumour genomics to explore options beyond routine care, or those establishing a molecular baseline to track disease progression over time.
₹2,50,000 — The Execution Bundle
Every Signature Baseline test automatically includes 3 months of full Blueprint Care (valued at ₹8,000/month) alongside an in-person multidisciplinary KCCIRC Tumour Board Review to transition your results into an actionable treatment roadmap.
- 118-Gene Targeted Panel: SNVs, InDels & 15 Fusions
- Tumour Fraction (TFx) Estimate: Assess overall tumour burden
- Sentinel Prerequisite: The required baseline for continuous monitoring
- 3 Months of Blueprint Care: Execution bundled in
- KCCIRC Tumour Board: In-person multidisciplinary review
The essential molecular foundation.
Standard testing looks primarily at the organ. Signature Baseline looks at the deeply targeted genetic drivers.
The Sentinel Prerequisite
This test is the required foundational step for Onkommon Sentinel. It captures the initial molecular fingerprint before treatment starts, acting as the critical baseline we use to track the cancer's recurrence or drug resistance via continuous blood monitoring later.
Targeted Affordability
By focusing specifically on 118 genes with known, actionable drug targets rather than the entire genome, we lower the financial barrier to precision oncology while still capturing the most critical data.
Non-Invasive Clarity
The extraction of ctDNA from blood is fully recognized by international clinical guidelines as a valid method to identify mutations and direct targeted therapies without the need for painful, invasive surgical biopsies.
Included vs. Excluded.
To ensure absolute transparency, it is critical to understand the boundaries of this targeted panel compared to our larger Signature Complete CGP test.
What is Included
- SNVs & InDels: High-depth analysis across 118 clinically significant genes.
- Fusions: Testing across 15 critical genes known for clinically actionable rearrangements.
- Tumour Fraction (TFx) Estimates: A calculation of the proportion of cell-free DNA in your blood that is actively shedding from the tumour, serving as a powerful biomarker to assess overall tumour burden.
What is Excluded
In order to keep the cost and turnaround time of the Signature Baseline highly accessible, it does not include:
- Tumour Mutational Burden (TMB)
- Microsatellite Instability (MSI)
- Copy Number Variations (CNVs)
If you require TMB or MSI analysis to determine eligibility for advanced Immunotherapies, you must upgrade to the 523-gene Signature Complete CGP or the Signature Tissue Full panel.
If actionable targets are found.
Like all Onkommon genomic testing, we do not simply hand you raw data. Our intelligence engine provides your oncologist with a structured war plan.
Therapies with Resistance
We flag targeted mutations that cause resistance to standard therapies, protecting you from toxic treatments that biologically will not work.
Off-Label & Cross-Tumor Approvals
We map your specific mutations to global literature, justifying the use of targeted therapies that may be approved for other cancer types.
Biosimilar Mapping
We automatically pair expensive international branded therapies with clinically equivalent, CDSCO-approved biosimilars available in India to reduce your financial burden.
Live Clinical Trial Matching
Your targeted profile is cross-referenced directly against active trial registries in India (CTRI) and globally to highlight accessible clinical options.
118 genes. Rigorous sequencing.
The Signature Baseline panel provides rigorous sequencing across the following genes, selected strictly based on global clinical significance.
ABL1, AKT1, ALK, APC, AR, ARAF, ARID1A, ARID1B, ATM, ATRX, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDKN2A, CHEK1, CHEK2, CSF1R, CTNNB1, EGFR, ERBB2, ERCC2, ESR1, FANCL, FGFR1, FGFR2, FGFR3, FOXL2, HNF1A, HRAS, IDH1, IDH2, INPP4B, KIT, KRAS, MET, MLH1, MSH2, MSH6, MUTYH, NF1, NRAS, NTRK1, NTRK3, PALB2, PDGFRA, PIK3CA, PMS2, POLD1, POLE, PPP2R2A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, RB1, RET, ROS1, SMAD4, SMARCB1, SRC, STK11, TP53, TSC1, TSC2, VHL.
Includes comprehensive coverage for MET exon 14 skipping mutations.
From blood draw to battle plan.
Sample collection kits are intended strictly for use by qualified phlebotomists and are not for patient self-testing.
Sample Collection
A specialized blood draw is completed by a phlebotomist at home or in clinic.
Targeted Sequencing
Cell-free DNA (cfDNA) is extracted and sequenced using advanced NGS platforms.
Computational Translation
Our engine analyzes the 118 genes and maps targets directly to accessible Indian drugs.
Medical Board & Delivery
A Medical Oncologist signs off, and your Navigator helps you execute the roadmap.
Critical limitations & transparency.
Results must always be interpreted by a qualified healthcare professional in conjunction with your full clinical history and other diagnostic test results.
DNA Shedding Variables
Not all cancers release enough DNA into the blood. Therefore, a normal result (no reportable changes detected) does not completely rule out the presence of active cancer or underlying genetic mutations.
Clonal Hematopoiesis
Occasionally, detected DNA changes found in the blood can originate from completely normal aging blood cells rather than the tumour itself.
Test Boundaries
This targeted test looks specifically at 118 genes; it does not detect every possible cancer mutation across the genome.
Supportive Tooling
The test cannot independently dictate treatment. It is an intelligence tool designed to support, not replace, formal medical advice and standard clinical guidelines.
Regulatory Compliance
Onkommon genomic tests are registered and comply with CDSCO and ICMR guidelines for in vitro diagnostic medical devices, utilized strictly for qualitative identification of somatic variants.
Frequently Asked Questions
Everything you need to know about Signature Baseline.
It is a genomic (DNA-based) test designed to look for highly targeted genetic changes in cancer using a simple blood sample. By analysing fragments of circulating tumour DNA (ctDNA) shed by the tumour, we can define the cancer's genetic features without needing a painful tissue biopsy.
The test will yield one of four outcomes: It may successfully identify genetic changes linked to specific treatments; it may show no reportable changes; it may identify changes whose significance is not yet fully understood (VUS); or, occasionally, it may be unable to produce a result due to severe sample degradation.
Not necessarily. While the test heavily highlights genetic features linked to certain targeted treatments, biosimilars, or trials, it does not guarantee immediate access to a specific medicine, specific health insurance/PAP approval, or that a treatment will definitively cure the cancer. Your doctor makes the final clinical decision.
This is exactly why Signature Baseline comes with 3 months of Blueprint Care. If the test identifies an expensive targeted therapy, your dedicated Onkommon Care Coordinator steps in immediately to handle the grueling paperwork for Patient Assistance Programs (PAPs), fighting to get you the medication at the lowest possible cost.
If you have Stage 4, highly refractory, or rare cancer, or if you need to know if you are eligible for Immunotherapy (which requires MSI and TMB testing), the 523-gene panel is vastly superior. If you need a more affordable entry into targeted therapies, or if you need to establish a molecular baseline to track your disease via continuous Sentinel blood monitoring, this 118-gene Baseline test is ideal.